SEC Comment Letter for VERTEX PHARMACEUTICALS (VRTX) — Jun 1, 2011
VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320)
Date: June 1, 2011 · CIK: 0000875320 · Accession: 0000000000-11-033774
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19319
Letter
June 1, 2011
Matthew W. Emmens Chief Executive Officer Vertex Pharmaceuticals Incorporated 130 Waverly Street Cambridge, Massachusetts 02139-4242 Re: Vertex Pharmaceuticals Incorporated Form 10-K Filed February 17, 2010 File No. 000-19319 Dear Mr. Emmens: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely,
Jeffrey Riedler Assistant Director
Show Raw Text
June 1, 2011 Matthew W. Emmens Chief Executive Officer Vertex Pharmaceuticals Incorporated 130 Waverly Street Cambridge, Massachusetts 02139-4242 Re: Vertex Pharmaceuticals Incorporated Form 10-K Filed February 17, 2010 File No. 000-19319 Dear Mr. Emmens: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, Jeffrey Riedler Assistant Director